Rhythm Express https://validator.w3.org/feed/docs/rss2.html Thank you for your submission. Senior DevOps Engineer Rhythm Express Receives Vizient Supplier Contract Signal Processing AI Engineer Clininal Specialist Senior SecOps Engineer Regional Sales Representative Rhythm Express Fact Sheet: Business Models and Benefits Next Level Cardiac Monitoring Careers Contact About Providers Territory Sales Manager Patient Quick Start Guide News Conventions Contact Us, Rhythm Express Patients Marketing Manager – Remote Cardiac Monitoring About Editing Draft Physician Use Guide Rhythm Express Named by Inc. Magazine as One of the Fastest Growing Private Firms in America – AGAIN! VivaQuant Releases AE-1010 Rhythm Express Software FAQs The Monitor Customer & Technical Support The Business Model Evaluation of an algorithm for highly automated measurements of QT interval. Validation of a novel system for preclinical assessment of ventricular arrhythmias. Application Minneapolis Star Tribune: VivaQuant is making an intriguing bet on equity crowdfunding VivaQuant Recognized by Inc. Magazine as One of the Fastest Growing Private Companies in America Once Again, VivaQuant Recognized by Inc. Magazine as One of the Fastest Growing Private Companies in America Impact of noise on ECG interval measurement in nonhuman primates. Evaluation of an in-line filter for reducing noise in subcutaneous telemetered ECGs. New surface ECG analysis technique reduces variability and increases data density.   A new system for assessment of intervals and arrhythmias in surface ECGs. Home Editing Draft 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Comparison of two highly automated ECG algorithms for detection of drug-induced cardiac ion channel block. Comparison of Comparison of one- and three-lead ECG to measure cardiac intervals and differentiate drug-induced multi-channel block. Comparison of Electrocardiographic Biomarkers for Differentiating Drug-Induced Single vs. Multiple Cardiac Ion Channel Block. VivaQuant Awarded Federal Funding to Develop a Comfortable, Accurate and Efficient Wearable for Patients with Atrial Fibrillation Patient Use Guide VivaQuant and DSI Announce Agreement VivaQuant Rhythm Express software demonstrates improved accuracy of cardiac safety assessment markers VivaQuant Celebrates Eight Years of Success VivaQuant Technology Shows Promise for Improving Drug Safety Assessment Accuracy VivaQuant Inks Collaboration with FDA to Improve Accuracy of Drug Cardiac Safety Assessment Home